The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports emerge of a fifth human case of H5N1 flu linked to ongoing outb
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and
CSL Seqirus has agreed to provide 665,000 doses of a bird flu vaccine to the European Commission as part of the EU’s efforts to prepare for a potential outbreak of the disease, with a
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss
A man in Mexico has died in what the World Health Organization (WHO) has said is the first lab-confirmed human infection with the H5N2 strain of bird flu.
COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.